Consulting and PK/PD Modelling Services for Preclinical and Clinical Biotherapeutics Development
Mission
We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.
Services
Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection and dose / regimen finding studies.
Why choose us
Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.
Partners
LYO-X is member of the iBx Network. We provide integrated consulting in toxicology, pathology, preclinical and clinical pharmacology and regulatory strategies.
LYO-X is partnering with Lixoft to provide you access to Monolix the scientifically and technologically most advanced software for preclinical and clinical data analysis.
LYO-X Kurzgesagt
Small Data Big Results
Learn more why Systems Pharmacology is a critical tool for the development of novel Biologics
-
Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model
April 17, 2020Fabian Bernhard, Rajesh Odedra, Sylvie Sordello, Rossella Cardin, Samantha Franzoni, Cédric Charrier, Adam Belley, Peter Warn, Matthias Machacek, Philipp Knechtle Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhibitor developed in combination with cefepime for empiric treatment of serious Gram-negative infections in … Read More
-
The Exposure Response Relationship of Enmetazobactam, Combined with Cefepime, is Best Described by f T > C T in a Murine Thigh Infection Model
October 4, 2019F. Berhard 1, M. Machacek 1, P. Warn 2, R. Odedra 2, S. Sordello 2, A. Belley 3, P. Knechtle 3 1 LYO-X Allschwil CH; 2 Evotec Cheshire UK; 3 Allecra Therapeutics Saint-Louis FR ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance • September 3-6, 2019 … Read More
-
Pharmacodynamic Targets of Enmetazobactam, Combined with Cefepime, against ESBL Producing Isolates of K. pneumoniae in a Murine Thigh Infection Model
October 4, 2019P. Warn 1 , R. Odedra 1 , S. Sordello 1 , F. Berhard 2 , M. Machacek 2 , A. Belley 3 , P. Knechtle 3 1 Evotec Cheshire UK; 2 LYO-X Allschwil CH; 3 Allecra Therapeutics Saint Louis FR. ASM-ESCMID Conference on Drug Development to Meet the … Read More
-
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
August 23, 2019Katherine Griffiths, Uli Binder, William McDowell, Rita Tommasi, Mark Frigerio, William G. Darby, Chris G. Hosking, Lionel Renaud, Matthias Machacek, Peter Lloyd, Arne Skerra & Michael Foley. mAbs, 2019 Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance … Read More